Results 1 to 10 of about 2,899,588 (264)
Frontiers in Endocrinology, 2023 Endocrine therapy is the prominent strategy for the treatment of hormone-positive breast cancers. The emergence of resistance to endocrine therapy is a major health concern among hormone-positive breast cancer patients.
Jie Yuan +11 more
doaj +3 more sources
Primary endocrine therapy of locally advanced breast cancer patients [PDF]
Archive of Oncology, 2003 Primary endocrine therapy has been traditionally reserved for elderly and unfit locally advanced breast cancer patients (LABC patients). In this group, the primary endocrine therapy could not be adequately compared to primary chemotherapy.
Nešković-Konstantinović Zora B.
doaj +1 more source
Frontiers in Oncology, 2021 PurposeTo evaluate the cost-effectiveness of adding ribociclib to endocrine therapy for pre/perimenopausal women with hormone receptor-positive (HR+), human epidermal receptor 2-negative (HER2-) advanced breast cancer from the US payer perspective ...
Eunae Jeong +4 more
doaj +1 more source
Frontiers in Oncology, 2022 PurposeThe purpose of this study was to evaluate endocrine therapy and chemotherapy for first-line, maintenance, and second-line treatment of hormone receptor-positive HER-2-negative metastatic breast cancer (HR+HER-2-MBC) and the relationship between ...
Qiuyue Liu +6 more
doaj +1 more source
Current Oncology, 2022 Omission of radiotherapy among older women taking 5 years of adjuvant endocrine therapy following breast conserving surgery for early-stage, hormone sensitive breast cancers is well-studied. However, endocrine therapy toxicities are significant, and many
Susan G. R. McDuff, Rachel C. Blitzblau
doaj +1 more source
Chinese Medical Journal, 2020 . Increasing numbers of targeted drugs are used in hormone receptor (HR)-positive metastatic breast cancer (MBC) to overcome or delay resistance to endocrine therapy.
Li Bian +3 more
doaj +1 more source
Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
Cancer Cell International, 2021 Drug resistance is always a great obstacle in any endocrine therapy of breast cancer. Although the combination of endocrine therapy and targeted therapy has been shown to significantly improve prognosis, refractory endocrine resistance is still common ...
Jing Chen +6 more
doaj +1 more source
Cell Transplantation, 2013 Pig islets demonstrate significantly lower insulin secretion after glucose stimulation than human islets (stimulation index of ~12 vs. 2 for glucose 1 and 15 mM, respectively) due to a major difference in β- and α-cell composition in islets (60% and 25 ...
Sophie Vériter +5 more
doaj +1 more source
Therapeutic Advances in Medical Oncology, 2017 We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer.
Tomás Reinert, Carlos H. Barrios
doaj +1 more source
Cell Death and Disease, 2021 Glucocorticoids (GCs) are widely prescribed for their anti-inflammatory and immunosuppressive properties as a treatment for a variety of diseases. The use of GCs is associated with important side effects, including diabetogenic effects.
Etienne Delangre +8 more
doaj +1 more source